-
公开(公告)号:SG173705A1
公开(公告)日:2011-09-29
申请号:SG2011058773
申请日:2010-03-05
Applicant: ABBOTT LAB
Inventor: HSIEH CHUNG-MING , HUGUNIN MARGARET , MURTAZA ANWAR , MCRAE BRADFORD L , KUTSKOVA YULIYA , MEMMOTT JOHN E , PEREZ JENNIFER M , ZHONG SUJU , TARCSA EDIT , CLABBERS ANCA , WALLACE CRAIG , BRYANT SHAUGHN H , LEDDY MARY R
Abstract: Proteins that bind IL- 17 and/or IL- 17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL- 17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
-
公开(公告)号:MX2011009362A
公开(公告)日:2011-09-26
申请号:MX2011009362
申请日:2010-03-05
Applicant: ABBOTT LAB
Inventor: HSIEH CHUNG-MING , LEDDY MARY R , PEREZ JENNIFER M , HUGUNIN MARGARET , MURTAZA ANWAR , TARCSA EDIT , MEMMOTT JOHN E , MCRAE BRADFORD L , KUTSKOVA YULIYA , ZHONG SUJU , CLABBERS ANCA , WALLACE CRAIG , BRYANT SHAUGHN H
IPC: A61K39/395
Abstract: Se describen proteínas que se unen a IL-17 y/o IL-17F junto con su uso en composiciones y métodos para tratar, prevenir, y diagnosticar enfermedades relacionadas con IL-17 y para detectar IL17 en células, tejidos, muestras, y composiciones.
-
公开(公告)号:ZA201007885B
公开(公告)日:2011-07-27
申请号:ZA201007885
申请日:2010-11-03
Applicant: ABBOTT LAB , ABBOTT GMBH & CO KG
Inventor: FOX GERARD B , DIGIAMMARINO ENRICO L , LOEBBERT RALF , HARLAN JOHN E , LUO FENG , WU ZHEN , HSIEH CHUNG-MING , NIMMRICH VOLKER , GU JIJIE , SCHMIDT MARTIN , EBERT ULRICH , MUELLER REINHOLD
Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid ß and advanced glycation-end-products.
-
公开(公告)号:CA2775402A1
公开(公告)日:2011-04-21
申请号:CA2775402
申请日:2010-10-15
Applicant: ABBOTT LAB
Inventor: HSIEH CHUNG-MING , WU CHENGBIN , MILLER RENEE , AMBROSI DOMINIC J
IPC: C07K16/24 , A61K39/395 , C07K16/46 , C12N15/13 , G01N33/53
Abstract: The present invention describes IL-1ß binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1ß. Binding proteins of the invention have high affinity for IL-1ß and neutralize IL-1ß activity. A binding protein of the invention can be a full-length antibody or an IL-1ß -binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1ß binding proteins of the invention are useful for detecting IL-1ß and for inhibiting IL-1ß activity, including in a human subject suffering from a disease or disorder in which IL-1ß activity is detrimental.
-
95.
公开(公告)号:AR071698A1
公开(公告)日:2010-07-07
申请号:ARP090101682
申请日:2009-05-08
Applicant: ABBOTT GMBH & CO KG , ABBOTT LAB
Inventor: LOEBBERT RALF , WU ZHEN , GU JIJIE , HSIEH CHUNG-MING , FOX GERARD B , SCHMIDT MARTIN , HARLAN JOHN E , LUO FENG , MUELLER REINHOLD , DIGIAMMARINO ENRICO L , EBERT ULRICH , NIMMRICH VOLKER
Abstract: Prote¡nas aisladas, en particular anticuerpos monoclonales, en particular anticuerpos humanizados, con injertos de CDR, que se unen a una prote¡na RAGE. Espec¡ficamente, estos anticuerpos tienen la capacidad de inhibir la union de RAGE a sus diversos ligandos. Los anticuerpos, o porciones de los mismos, que se describen en la presente solicitud son de utilidad para el tratamiento de una enfermedad o trastorno caracterizado por, o inducido por, ligandos fisiopatologicos de RAGE, por ejemplo prote¡nas mal plegadas como el beta amiloide y productos finales de glicosilacion avanzada.
-
公开(公告)号:AR070709A1
公开(公告)日:2010-04-28
申请号:ARP090100700
申请日:2009-02-27
Applicant: ABBOTT LAB , ABBOTT GMBH & CO KG
Inventor: SCHMIDT MARTIN , MUELLER BERNHARD K , HSIEH CHUNG-MING , BARLOW EVE H , LEDDY MARY R , BARDWELL PHILLIP D
Abstract: Proteínas aisladas, particularmente anticuerpos monoclonales, que se unen y neutralizan la proteína RGM A. Específicamente, estos anticuerpos tienen la capacidad de inhibir la union de RGM A a su receptor y/o sus correceptores. Los anticuerpos o sus porciones, son utiles para detectar RGM A e inhibir la actividad de RGM A, por ejemplo, en un ser humano afectado por un trastorno que incluye, no taxativamente, esclerosis multiple, traumatismo cerebral en mamíferos, lesiones en la médula espinal, accidente cerebrovascular, enfermedades neurodegenerativas, y esquizofrenia.
-
-
-
-
-